DDInter1577 DDInter1376
Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of several hormone-responsive conditions. It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids, and more recently by the United States' FDA in 2020, under the brand name Orgovyx, for the treatment of advanced prostate cancer.[L27991,L27996] This branded product was later approved by the European Commission on April 29, 2022. Relugolix has also been studied in the symptomatic treatment of endometriosis. Relugolix is the first (and currently only) orally-administered GnRH receptor antagonist approved for the treatment of prostate cancer - similar therapies such as [degarelix] require subcutaneous administration - and therefore provides a less burdensome therapeutic option for patients who might otherwise require clinic visits for administration
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Relugolix {u} may cause a minor interaction that can limit clinical effects when taken with {v} Enzalutamide
Relugolix {u} may cause a minor interaction that can limit clinical effects when taken with {v} Brigatinib
Relugolix {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Formoterol
Relugolix {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Relugolix {u} may lead to a major life threatening interaction when taken with {v} Ticagrelor
Relugolix {u} may lead to a major life threatening interaction when taken with {v} Elagolix
Relugolix may cause a minor interaction that can limit clinical effects when taken with Enzalutamide
Relugolix may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Relugolix may cause a moderate interaction that could exacerbate diseases when taken with Formoterol
Relugolix may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Relugolix may lead to a major life threatening interaction when taken with Ticagrelor
Relugolix may lead to a major life threatening interaction when taken with Elagolix